• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Everybody Loves a Comeback: Is GameStop's a Trick or Treat?

Let's see if this is just another head fake, or the real thing, like that of my personal fave A-Treat.
By JONATHAN HELLER
Sep 18, 2020 | 11:00 AM EDT
Stocks quotes in this article: EBAY, AMZN, GME

In 2015, A-Treat bottling company, an Allentown, Penn.-based beverage company, went out of business after a 97-year run. It was a regional favorite for generations in my family and others -- I actually found it in Bermuda on our honeymoon in the early 90s -- and it was sad to see it close its doors.

At the time, I found inventory at a Lancaster grocery store, but you could also find last batches on eBay (EBAY) and Amazon (AMZN) at ridiculous prices, but again, this was the last of it, as production stopped. Later that year however, A-Treat was purchased by a local company Jaindl, which has revived the brand (including some flavors made with cane sugar, served in glass bottles), and it's been back in stores for a few years, and seems to be thriving.

I can't resist a comeback story.

One of the more interesting ones that may be these playing out these days is that of gaming retailer GameStop (GME) , has seen sales, profits, and its stock price slide for several years.

In late 2013, GME traded in the high $50s; from there as the stock slid, it took on "value-trap" characteristics. It was a high-yielding stock, the company was buying back stock, raising the dividend, and trading at fairly low forward price-earnings ratios, but none of that was sustainable as the business deteriorated. The shares slid all the way to the mid-$2 range this past April. The dividend was eliminated in 2019.

Things started to get more interesting in August 2019, and GME ended up making the cut in this year's version of my Tax-Loss Selling Recovery Portfolio. I was not unaware at time, however, that I might finally be succumbing to the GME value-trap, which I'd resisted for years. Then, the story got more interesting this year, when some activist investors took aim at GME, and won board seats in June.

But that did not alter the revenue slide; second-quarter results released just last week showed revenue of $942 million, down 27% year-over-year, but more importantly missed the consensus by $78 million. The loss of $1.40 per share missed by $0.27, and shares fell 15% on September 10.

What a difference a few days makes, not to mention a couple of upgrades.

On Monday, Jefferies upgraded GME to "buy" while Telsey Advisory Group lifted the shares to "outperform." The shares closed at $9.20 on Thursday, up 48% since the earnings release. Bolstering the shares beyond the upgrades, is positive news on video-game sales, which rose 37% year over year in August.

There may be something else at work here. Short interest in GME is extraordinarily high, with 57.86 million shares sold short and total shares outstanding 65.162 million. A short squeeze is very possible here, but that's also been a familiar story for GME.

GME has done a decent job of cleaning up its balance sheet. Cash, as of August 1, stood at $735 million, or $11.28 per share. Debt (excluding operating lease liabilities) was $434 million, down from $615 million last year. That puts net/cash per share at $4.62.

Somehow, though, the company needs to return to profitability. The current consensus (remarkably, eight analysts follow the name), has it fairly close to breakeven next year, with a loss of $0.13 per share.

I love a comeback, and time will tell if this is just another head fake from GME, or the real thing, like that of A-Treat.

Have a great weekend!

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Heller was long GME.

TAGS: Short-selling | Earnings | Fundamental Analysis | Investing | Markets | Small Cap | Stocks | Value Investing | Analyst Actions

More from Stocks

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login